LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid COVID-19 Antigen Tests Less Effective at Detecting SARS-CoV-2 in People with Low Virus Levels, Finds Study

By LabMedica International staff writers
Posted on 22 Oct 2020
Print article
Illustration
Illustration
Researchers from the Erasmus University Medical Center (Rotterdam, the Netherlands) have cautioned that not all rapid COVID-19 antigen tests that provide results within 30 minutes may be equally effective at detecting the SARS-CoV-2 virus.

Their suggestion was based on data gathered from drive through testing stations using rapid antigen detection tests (RDTs), RT-PCR and virus culture, with the aim of assessing the ability of RDTs to detect infectious cases. Antigen-based assays detect specific surface proteins, or antigens, on SARS-CoV-2 particles, and are easy to use and inexpensive to produce. The researchers used five commercially available rapid antigen assays on samples from 1,754 people who had already tested positive for the SARS-CoV-2 virus with the standard PCR test, which is highly sensitive but slow.

The team found that the detection limits of the five commercially available RDTs differed considerably, impacting the translation into the detection of infectious cases. The two most sensitive tests detected the SARS-CoV-2 virus more than 97% of the time, whereas the least sensitive test detected the novel coronavirus in about 75% of the cases. All the samples came from people with COVID-19 symptoms, who tend to have high levels of the SARS-CoV-2 virus. Based on their findings, the researchers have cautioned that rapid antigen tests may be less effective at picking up the presence of the SARS-CoV-2 virus in people with low levels of the virus. The researchers have recommended careful fit-for-purpose testing before implementation of antigen RDTs in routine testing algorithms as part of the COVID-19 response.

Related Links:
Erasmus University Medical Center

Gold Member
COVID-19 TEST READER
COVID-19-CHECK-1 EASY READER+
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.